Positron emission tomography combined with computed tomography provides information about metabolic or molecular activity alongside detailed anatomical images. PET/CT may be used in selected cancers, inflammatory conditions and other disorders. The radiotracer and imaging protocol depend on the clinical indication and patient requirements.
Single-photon emission computed tomography combined with CT uses radioactive tracers to evaluate selected physiological processes and anatomical structures. The technique may assist in investigating bone, cardiac and other medical conditions. Imaging findings are interpreted alongside clinical information and related investigations.
Theranostics combines molecular imaging with targeted radionuclide treatment. Imaging helps identify whether a particular biological target is present and may support treatment selection. The approach is used for selected medical conditions and requires specialist assessment, monitoring and radiation safety measures.
Lutetium-177 PSMA therapy is a targeted radionuclide treatment used for selected patients with prostate cancer. A radioactive medicine binds to prostate-specific membrane antigen expressed by suitable tumour cells. Eligibility depends on cancer characteristics, molecular imaging, previous treatment and clinical criteria.
Lutetium-177 DOTATATE therapy, also called peptide receptor radionuclide therapy, is used for selected neuroendocrine tumours expressing somatostatin receptors. Molecular imaging helps establish suitability. Treatment requires monitoring for potential kidney, bone marrow and other treatment-related effects.
Radioactive iodine therapy uses iodine-131 for selected thyroid disorders, including certain thyroid cancers and hyperthyroidism. Treatment suitability depends on the diagnosis, thyroid function and other clinical factors. Patients receive appropriate radiation safety instructions and follow-up recommendations.
Oncological PET imaging assesses the distribution of selected radiotracers within the body to provide information relevant to cancer evaluation. Depending on the cancer type, it may assist in staging, treatment response assessment or suspected recurrence. Imaging findings require interpretation within the clinical context.
Cardiac PET imaging uses radiotracers to evaluate selected aspects of heart function and myocardial blood flow or metabolism. It may be considered for particular cardiovascular conditions. The imaging protocol and interpretation depend on the clinical indication and specialist assessment.
Nuclear medicine infection imaging helps identify metabolic or inflammatory activity associated with selected suspected infections. Different radiotracers and imaging methods may be used depending on the condition. Results are considered alongside examination, laboratory tests and other diagnostic findings.
Metabolic brain imaging uses specialised radiotracers to examine selected patterns of brain activity. It may contribute information during evaluation of certain neurological disorders. Interpretation requires consideration of symptoms, neurological findings and other imaging investigations.
PET/CT-guided biopsy uses molecular and anatomical imaging to help select or access an appropriate tissue sampling target. The collected sample is examined in a laboratory to establish or clarify a diagnosis. The procedure is considered when clinically appropriate and technically feasible.
PET-based radiotherapy planning incorporates molecular imaging information into selected cancer radiation treatment plans. Imaging may help identify metabolically active tumour areas and support target definition. Treatment planning is coordinated with radiation oncology and other relevant specialist teams.
Yttrium-90 skin patch brachytherapy uses a radioactive source placed close to selected superficial treatment targets. It is considered only for appropriate indications following specialist assessment. Treatment planning includes evaluation of the affected area, radiation dose and surrounding healthy skin.
Radiopharmaceutical preparation involves handling radioactive substances used for diagnostic imaging or treatment. Quality control procedures help verify suitable preparation and compliance with relevant safety standards. These activities require trained personnel, appropriate facilities and established radiation protection procedures.